Table of Contents

All the data and content are powered by ZXData, Learn more about ZXData

ZX Data private stock trade

Executive Summary

  • This quarter, reporting holders marked-down their private portfolios by 5.6% ($ weighted) with an average mark-down of 2.5% (equal weighted). The period saw three companies decline for every two advancing companies.
  • Sentiment up:
  • Sentiment down:
  • The difference between Fund Marks and ZX Index Values remains considerable with 96% of ZX Index companies showing a deviation of 5% or more versus Fund Marks.

Heat Map: May 31st, 2023 Reporting Period

-5.6%

Appreciation/Depreciation of All Reported Holdings1

-2.5%

Average Mark-Up/Mark-Down Across All Reported Holdings2
Tarana
90.7%
Cava
76.2%
Sonoma Bio
60.7%
D2iQ
54.8%
Dragonfly Therapeutics
53.9%
Quell
48.5%
FlixBus
38.1%
Astranis
33.9%
ElevateBio
32.1%
Conformal Medical
23.0%
Redwood Materials
22.9%
Generate Bio
21.3%
ServiceTitan
16.1%
Instacart
14.2%
Scorpion Therapeutics
14.2%
MNTN
12.7%
Blink Health
10.9%
Evozyne
10.6%
BETA Technologies
8.4%
Bytedance
7.2%
SambaNova
7.2%
Ankyra
6.1%
Verily
5.9%
LifeMine
5.1%
Dianthus
4.7%
Skyryse
4.7%
Deep Genomics
4.5%
Alif Semi
3.8%
PrognomIQ
3.6%
Bolt
3.3%
Castle Creek
2.9%
Korro Bio
2.5%
Ant Financial
1.9%
Rapyd
1.8%
DNA Script
1.7%
Unqork
1.7%
MOD Pizza
1.5%
FogPharma
1.0%
Rappi
0.7%
Einride
0.6%
Cleerly
0.5%
Tenstorrent
0.4%
CelLink
0.3%
Saluda Medical
0.3%
T-Knife
0.3%
Kardium
0.1%
A24 Films
0.0%
Accelerant
0.0%
Airtable
0.0%
Altos Labs
0.0%
Aristea Therapeutics
0.0%
Astera Labs
0.0%
Better.com
0.0%
Cadre
0.0%
Carta
0.0%
Celonis
0.0%
Cohesity
0.0%
Cross River
0.0%
Diamond Foundry
0.0%
Druva
0.0%
Element Bio
0.0%
Envoy
0.0%
Fabletics
0.0%
Faraday Pharma
0.0%
Figure Technologies
0.0%
Galvanize
0.0%
Harness
0.0%
Headspace
0.0%
Highspot
0.0%
Inscripta
0.0%
Intarcia Therapeutics
0.0%
Laronde
0.0%
MadHive
0.0%
Magic Leap
0.0%
Menlo Micro
0.0%
Patreon
0.0%
Resilience
0.0%
Savage X
0.0%
Scale AI
0.0%
Skyhawk
0.0%
SpaceX
0.0%
Talkdesk
0.0%
Thrasio
0.0%
VideoAmp
0.0%
Whoop
0.0%
Apogee Therapeutics
-0.1%
Waymo
-0.5%
Caris
-0.7%
GaN Systems
-1.0%
PsiQuantum
-1.1%
Freenome
-1.3%
Lime
-1.5%
Enevate
-1.7%
JUUL
-2.3%
Adimab
-2.6%
Stripe
-3.3%
Xsight Labs
-3.4%
Fanatics
-4.2%
X Holdings
-4.4%
Treeline Bio
-4.7%
Bright Peak
-4.8%
ABL Space
-5.0%
Asimov
-5.0%
Databricks
-5.0%
Boundless Bio
-5.5%
Tempus Labs
-5.5%
Tipalti
-5.5%
Aledade
-6.0%
Wugen
-6.2%
Tory Burch
-6.7%
SiMa ai
-6.9%
Odyssey Therapeutics
-7.5%
Starling Bank
-7.6%
Pine Labs
-7.8%
Algolia
-8.6%
Thriveworks
-8.9%
Omada Health
-9.5%
Canva
-9.6%
SalioGen
-9.6%
Arctic Wolf
-10.0%
Relativity Space
-10.1%
Grammarly
-10.2%
Reddit
-10.7%
RefleXion Medical
-11.0%
Meesho
-11.3%
Epic Games
-11.7%
FLEXE
-11.8%
BYJU's
-12.2%
Bombas
-12.8%
Discord
-13.4%
GupShup
-13.6%
Dataminr
-14.8%
Checkr
-16.7%
Seismic
-17.6%
Chime
-18.1%
Caidya (dMed)
-18.2%
Goop
-18.7%
Signifyd
-19.4%
Convoy
-21.2%
Farmers Business Network
-22.1%
AgBiome
-23.3%
Circle
-26.8%
Honor Tech
-29.6%
MasterClass
-31.8%
Sila Nano
-34.9%
goPuff
-35.7%
HaulHub
-35.9%
Insitro
-37.0%
Rad Power
-45.2%
Bowery
-54.1%
Nuro
-55.3%
Heal
-75.7%
Color Genomics
-77.3%
Bolt Threads
-91.2%

1 Dollar-weighted return on all reported holdings
2 Equal-weighted mark-up or mark-down across all reported holdings

This quarter, reporting holders marked down their private portfolios by 5.6% ($ weighted) with an average mark-down of 2.5% (equal weighted). The period saw three companies decline for every two advancing companies.

Tarana experienced the most significant mark-up, followed by Cava, Sonoma Bio and D2iQ. Biotechnology, HealthTech and Aerospace & Defense saw the largest mark-ups across sectors.

Bolt Threads experienced the most significant mark-down, while Color Genomics, Heal and Nuro also experienced notable mark-downs. Among the sectors, AgTech, Crypto & Blockchain and EdTech saw the largest mark-downs.

Comparison of ZX Index Value vs. Fund Marks

CompaniesZX Index Value vs. Fund Marks
Color Genomics+223.28%
Figma+139.67%
MasterClass+125.07%
Intercom+98.92%
Sila Nano+92.31%
goPuff+90.63%
Canva+75.30%
Convoy+60.30%
Everly Health+57.64%
Nuro+51.45%
Dataminr+36.58%
Chime+30.73%
Figure Technologies+30.70%
6Sense+27.69%
Cross River+24.05%
Patreon+18.55%
Carta+18.01%
Relativity Space+17.06%
Redwood Materials+13.58%
Tekion+11.76%
Highspot+10.00%
Scale AI+9.23%
Databricks+8.15%
SpaceX+6.58%
BYJU’s+5.68%
GupShup+5.37%
Stripe+4.81%
Circle+2.57%
Flexport+2.33%
Airtable+0.58%
ThoughtSpot-4.32%
Instacart-5.48%
Harness-5.99%
Talkdesk-6.05%
Algolia-6.22%
ServiceTitan-9.85%
Reddit-12.20%
Discord-12.81%
Rapyd-25.63%
VideoAmp-26.06%
Rappi-26.60%
Astranis-26.92%
Shipbob-27.38%
Cohesity-31.08%
Epic Games-31.93%
MNTN-34.96%
Arctic Wolf-36.06%
Celonis-36.45%
Bytedance-40.25%
Farmers Business Network-48.98%
SambaNova-55.90%
Diamond Foundry-61.29%
Better.com-88.89%

The difference between Fund Marks and ZX Index Values remains considerable with 96% of ZX Index companies showing a deviation of 5% or more versus Fund Marks. Among the companies, Color Genomics, Figma and MasterClass had the highest variance in reported marks versus ZX Index Values. Better.com, Diamond Foundry and SambaNova had the lowest variance in reported marks versus ZX Index Values.

Highest Variance in Reported Marks
CompanyNormalized Std Dev3$ Weighted AvgMaxMin
Rapyd.28$60.72$74.28$39.37
Saluda Medical.17$10.32$11.61$8.06
Grammarly.17$19.94$26.21$18.00
Unqork.16$7.51$8.49$5.89
Waymo.16$86.96$91.72$38.14

3 Normalized Standard Deviation is used to express the measure of spread across reported marks and allows for comparison between companies independent of their price per share based on a dollar-weighted average.

This period, Rapyd ($39.37 - $74.28) saw the highest share price variance across funds followed by Saluda Medical ($8.06 - $11.61) and Grammarly ($18.00 - $26.21).

Positive Trend Reversal4 (# = consecutive prior qtrs marked down or flat)
Negative Trend Reversal5 (# = consecutive prior qtrs marked up or flat)
Positive Trend Reversal4 (# = consecutive prior qtrs marked down or flat)
Ant Financial
10
Instacart
8
Redwood Materials
7
Rappi, Service Titan, Waymo
6
Negative Trend Reversal5 (# = consecutive prior qtrs marked up or flat)
Fanatics
10
Freenome, HaulHub
7
PrognomIQ, PsiQuantum
7
Reflexion Medical, Tempus Labs
7

4 Positive Trend Reversal reflects an individual holding marked up after consecutive quarterly periods marked down or flat
5 Negative Trend Reversal reflects an individual holding marked down after consecutive quarterly periods marked up or flat

Ant Financial saw its first positive reversal in ten quarters while Instacart saw its first positive reversal in two years. Fanatics saw their first negative reversal in ten quarters.

Disclaimer

This report is based on data reported by 270+ funds and $47 billion+ of value. Many holders of private company shares do not report their holding values and are thus not included in this report’s dataset. Further, many venture-backed private companies are not held by any reporting funds and are thus not included in this report. As such, this report should not be construed as providing a complete picture of shareholder sentiment or venture-backed private company performance. This report does not constitute investment advice or a "research report" as defined by FINRA Rules.

The “ZX Index Value” is derived by applying proprietary weightings to the order flow data collected for the stated period (both bids and asks), based on the order type (firm order or indication of interest) and whether the order has been executed, with greater weight given to more recent orders.

Zanbato, Inc. (“Zanbato”) prepares and disseminates market information about venture-backed private company securities, and the current bids and offers for those securities listed on the ATS operated by Zanbato (“ZX”). The information provided in this report has been prepared by sales, trading, or other non-research functions. Pricing indications and macro commentary are provided for factual information purposes only. This report is not intended to assess the individual merits of a particular investment or strategy, does not constitute a recommendation to buy or sell any financial instrument or to participate in any trading strategy and should not be construed as such. This report does not constitute investment advice. Certain information in this report has been obtained from third party sources and, while such information is believed by Zanbato to be reliable, it has not been independently verified by Zanbato and Zanbato shall not be responsible or liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with any use of, or reliance on, such third party information. Furthermore, the information contained in this report may not be current due to, among other things, changes in the financial markets or economic environment. Zanbato does not, and has no obligation to, update any such information contained in this report. Any prices or quotations contained herein are indicative only, do not represent firm quotes as to either price or size and should not be used for valuation purposes.

yukacon_arrow_up_right